# OnCo record paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023" ;
  schema:name "Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)"@en ;
  schema:description "Phase 2 or 3 results paper on Ciltacabtagene autoleucel in Multiple myeloma, in Journal of Clinical Oncology (2023), one of the most cited Europe PMC records with Ciltacabtagene autoleucel in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.22.00690>, <https://pubmed.ncbi.nlm.nih.gov/36269898/>, <https://europepmc.org/article/MED/36269898> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1200/jco.22.00690> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Mi JQ, Zhao W, Jing H, et al." ;
  onco:journals <https://onco.cc/journals/jco/> .